Dry Powder Inhalation: Technology, Devices, Markets and Opportunities

NEW YORK, Jan. 19, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Dry Powder Inhalation: Technology, Devices, Markets and Opportunities

http://www.reportlinker.com/p0761242/Dry-Powder-Inhalation-Technology-Devices-Markets-and-Opportunities.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

Advances in drug formulation and inhalation device design are creating new opportunities for inhaled drug delivery as an alternative to oral and parenteral delivery methods. Much of the interest in pulmonary delivery of systemic drug therapies is focused on chronic diseases and refractory conditions – aliments that require frequent drug administration for a protracted period of time. While several approaches for delivering active substances to, and systematically via, the lungs compete in this space, recent advances and investment in powder formulations, particle engineering, and device architecture have positioned dry powder inhalation (DPI) as a formidable challenger to more established pulmonary methods such as metered dose inhalers and nebulizers. While evolving DPI technology and combination therapeutic products continue to have a significant impact on the treatment of upper respiratory diseases and conditions, dry powder inhalers are making strides in applications requiring the systemic delivery of both small and large molecule and engineered macromolecules for the treatment of a range of pathologies.

• Examines Dry Powder Inhaler design issues and evolving market factors

• Forecasts the impact of DPI technology and devices on drug delivery markets and projects probable future developments

• Provides forecasts of DPI combination product demand by indication and drug class to 2016

• Profiles Dry Powder Inhalation market participants, their technology, product development activity, and business strategies

Devices, Formulations and Market EvolutionEstablished Therapeutic TargetsEmerging TherapiesDemographics and GrowthCompeting TechnologiesMarket DriversRisk Factors

Dry Powder Inhalation Technology

Dry Powder FormulationsDry Powder Particle Technology & Powder EngineeringDry Powder FormulationsDry Powder ProcessingDry Powder PackagingEmerging FormulationsDry Powder InhalersDPI Device CharacteristicsDPI Design Parameters

DPI Device Assessments

Acu-Breathe (Respirics)Aerolizer Novartis)AIR (Civitas/Alkermes)Airmax (Teva)Aspirair (Vectura)Axahaler (S.M.B.)Breezhaler (Novartis)Clickhaler (Vectura)Conix Dry (3M)Cricket (Mannkind)Cyclohaler (Teva)Diskhaler (GlaxoSmithKline)Diskus (GlaxoSmithKline)Dreamboat (Mannkind)Easyhaler (Orion)EZ Aer (Aerovance)Flexhaler (AstraZeneca)Genuair (Almirall)Gemini (GSK)Handihaler Boehringer Ingelheim)MicroDose (MicroDose Therapeutx)Next DPI (Chiesi)Novolizer (Meda)Oximax (Mantecorp)Podhaler (Novartis)Pulmojet (sanofi-aventis)Pulvinal (Chiesi)Skyehaler (SKyepharma)Solis (Sandoz/Novartis)Taifun (Akela)Taper Dry (3M)Trivair (Trimel Bipharma)Twincaps/Flowcaps (Hovione)Twisthaler (Schering /Merck)Turbuhaler (AstraZeneca)

Dry Powder Inhalation – Therapeutic Segment Analysis & Forecasts

Upper Respiratory IndicationsDisease SegmentsTherapeutic LandscapePrescribing Trends and Growth FactorsSystemic Drug DeliveryBioterrorDiabetesHereditary DiseasesCystic FibrosisInfectious DiseasesOsteoporosisNeurologyPain Management

Market Factors

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker